Ibex Medical Analytics Receives FDA 510(k) Clearance for AI-Powered Prostate Cancer Detection
Ibex Medical Analytics has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, marking a major milestone in the advancement of AI-driven pathology solutions. This in vitro diagnostic medical device leverages artificial intelligence to analyze prostate biopsies, generating heatmaps that help pathologists identify small and rare missed prostatic cancers, enhancing diagnostic accuracy and patient outcomes.
Prostate cancer remains one of the most common cancers globally, affecting one in eight men in their lifetime, with cases expected to double by 2040. “AI-powered pathology solutions can support pathologists in delivering more precise and efficient diagnoses, which is critical in improving patient outcomes,” said Dr. Mahul B. Amin, Ibex scientific advisor and Vice President and Medical Director of Labcorp’s Hospital Systems Operating Division.
Ibex Prostate Detect was clinically validated through rigorous studies in multiple U.S. and European laboratories as part of the FDA clearance process. The system demonstrated a 99.6% positive predictive value (PPV) for cancer heatmap accuracy and identified a 13% rate of missed cancers in initially benign-diagnosed cases. These findings, later confirmed by expert pathologists, highlight the clinical utility of AI-powered pathology solutions in reducing diagnostic errors and improving patient care.
“The FDA clearance represents a pivotal step in Ibex’s mission to deliver clinically validated AI solutions that enhance cancer diagnostics,” said Joseph Mossel, CEO of Ibex Medical Analytics. “This achievement reinforces our commitment to patient safety, innovation, and the broader adoption of AI-powered digital pathology in clinical practice.”
As global cancer rates rise and pathology workloads increase, Ibex’s platform plays a crucial role in enhancing diagnostic accuracy and streamlining workflows amid a growing shortage of pathologists. Already deployed worldwide, Ibex’s AI solutions support cancer detection in prostate, breast, and gastric pathology, with regulatory certifications across the EU, UK, Australia, and Brazil. With FDA clearance now secured for Prostate Detect, Ibex continues to advance AI-driven pathology solutions that empower clinicians and improve cancer care.
